Sibylla Biotech SpA

Sibylla is an early-stage drug discovery company based on the enabling possibility of simulating the folding pathway from the amino acid sequence produced by the cell's ribosomes to the native state with atomic detail. Sibylla's computational platform identifies long-lived folding intermediate structures amenable to host druggable pockets, constituting a new class of pharmacological targets. Sibylla's small molecules bind the folding intermediate state and interfere with the folding process causing degradation. Well-differentiated in the TPD landscape, Sibylla's Folding Interfering Degraders can be used against undruggable proteins, delivering new therapies for untreatable diseases. The internal pipeline is now progressing toward preclinical validation.